22nd Century to Participate in the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7
October 01 2021 - 9:20AM
22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural
biotechnology and intellectual property company focused on
improving health and wellness through plant science, today
announced that the Company will participate in the upcoming
Benzinga Rising Stars: Catalytic Small Cap Growth Conference on
Thursday, October 7, 2021. The Company’s presentation will be
available for viewing that day at 12:15 p.m. ET on Benzinga’s live
stream channel or via a link on the Company’s Investor Relations
website under the Events subtab at:
www.xxiicentury.com/investors/events.
During his presentation, James A. Mish, chief executive
officer of 22nd Century Group, will highlight the Company’s
business development, commercialization, and value creation efforts
across its three high-value plant franchises: tobacco,
hemp/cannabis and hops.
About 22nd Century Group, Inc.22nd Century
Group, Inc. (Nasdaq: XXII) is a leading agricultural biotechnology
and intellectual property company focused on improving health and
wellness through plant science. 22nd Century uses modern plant
breeding technologies, gene-editing, and molecular breeding to
deliver value to its customers in the life science and consumer
products industries by creating new, proprietary tobacco,
hemp/cannabis and hop plants with optimized alkaloid and flavonoid
profiles as well as improved yields and valuable agronomic traits.
22nd Century was founded to build intellectual property related to
nicotine biosynthesis in the tobacco plant and to commercialize its
proprietary reduced nicotine content (RNC) tobacco plants, which
have become the cornerstone of FDA’s Comprehensive Plan to address
the enormous amount of death and disease caused by addiction to
smoking. The Company has also begun to leverage its plant science
expertise and existing partnerships to create and commercialize
new, proprietary hemp/cannabis and hop plants to optimize their
genetics and create valuable new intellectual property.
Learn more at xxiicentury.com, on
Twitter @_xxiicentury, and on LinkedIn.
Cautionary Note Regarding Forward-Looking
StatementsExcept for historical information, all of the
statements, expectations, and assumptions contained in this press
release are forward-looking statements. Forward-looking statements
typically contain terms such as “anticipate,” “believe,”
“consider,” “continue,” “could,” “estimate,” “expect,” “explore,”
“foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,”
“potential,” “predict,” “preliminary,” “probable,” “project,”
“promising,” “seek,” “should,” “will,” “would,” and similar
expressions. Actual results might differ materially from those
explicit or implicit in forward-looking statements. Important
factors that could cause actual results to differ materially are
set forth in “Risk Factors” in the Company’s Annual Report on Form
10-K filed on March 11, 2021. All information provided in this
release is as of the date hereof, and the Company assumes no
obligation to and does not intend to update these forward-looking
statements, except as required by law.
Investor Relations & Media
Contact:Mei KuoDirector, Communications & Investor
Relations22nd Century Group, Inc.(716)
300-1221mkuo@xxiicentury.com
22nd Century (NASDAQ:XXII)
Historical Stock Chart
From Aug 2024 to Sep 2024
22nd Century (NASDAQ:XXII)
Historical Stock Chart
From Sep 2023 to Sep 2024